BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
목요일, 9월 17

BioNTech SE

BNTXNASDAQ
Trade with Public
Trade with Public
$95.83
-0.86-0.89%
가까이에: Sep 16, 5:00 PM EST
$95.90
0.070.07%
시간외: 4:18 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

BioNTech Financials

BioNTech (BNTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est

BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
Benzinga Newsdesk

PRO
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the
Benzinga Newsdesk

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.
Vandana Singh

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est

BioNTech (NASDAQ:BNTX) affirms FY2026 sales outlook from $2.328 billion-$2.678 billion to $2.328 billion-$2.678 billion vs $2.560 billion estimate.
Benzinga Newsdesk

PRO
BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved